Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 6508-6508 ◽  
Author(s):  
J. C. Byrd ◽  
K. A. Blum ◽  
J. A. Burger ◽  
S. E. Coutre ◽  
J. P. Sharman ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Tyrosine Kinase ◽  
Lymphocytic Leukemia ◽  
Bruton’S Tyrosine Kinase ◽  
Small Lymphocytic Lymphoma ◽  
Bruton's Tyrosine Kinase ◽  
Phase Ib ◽  
Btk Inhibitor

scholarly journals Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

Blood ◽  
2014 ◽  
Vol 123 (8) ◽  
pp. 1207-1213 ◽  
Author(s):  
Jennifer A. Woyach ◽  
Engin Bojnik ◽  
Amy S. Ruppert ◽  
Matthew R. Stefanovski ◽  
Virginia M. Goettl ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Mouse Model ◽  
Tyrosine Kinase ◽  
Lymphocytic Leukemia ◽  
Bruton’S Tyrosine Kinase ◽  
Bruton's Tyrosine Kinase ◽  
Genetic Inactivation ◽  
Key Points

Key Points Kinase-functional BTK is important in the development and expansion of CLL. Both targeted genetic inactivation of BTK and inhibition of BTK by ibrutinib inhibit the development of CLL in the TCL1 mouse model.

Sign in / Sign up

Export Citation Format

Share Document